<DOC>
	<DOCNO>NCT00446251</DOCNO>
	<brief_summary>This 12-month phase 2 , prospective , open label study evaluate effect rituximab mycophenolate mofetil ( MMF ) PRA 14 highly sensitized patient complete 8 month trial MMF treatment alone . PRA value obtain study enrollment 6 12 month combine therapy well rate transplant compare evaluated use descriptive analysis .</brief_summary>
	<brief_title>Effects Rituximab Mycophenolate Mofetil ( MMF ) Highly Sensitized Patients Awaiting Renal Transplant</brief_title>
	<detailed_description>BACKGROUND : Patients expose human tissue prior transplant , blood transfusion pregnancy may develop maintain anti-bodies foreign human cell ( SENSITIZATION ) . As result sensitization patient likely reject organ donate individual posse similar human cell marker ( ANTIGENIC ) profile . These sensitized patient remain kidney transplant wait list twice long pre-sensitized . The Panel Reactive Antibodies ( PRA ) test panel use measure patient reactivity human leukocyte cell antigen ( HLA ) . A PRA 75 % mean patient react 75 % antigens panel . A high PRA indicate subject already antibodies highly SENSITIZED . Spontaneous decrease PRA titer rarely occur . Thus probability transplantation sensitize patient significantly decrease . RATIONALE use Rituximab : By reduce specific B-cell population Rituximab currently use treatment auto-immune disease lupus erythematosus rheumatoid arthritis cancer B-cell non-Hodgkin 's lymphoma . It report potential roll decrease anti-human lymphocyte ( HLA ) antibodies post transplant . More study need assess possible benefit among pre-transplant patient . Vierira et al . [ `` Rituxan reduction anti-HLA antibody patient await renal transplantation '' , Am J Transplantation 2002 ; 2 : A870 ] report use rituximab sensitize patient . Nine patient dialysis PRA &gt; 50 % treat rituximab ( n=3 per group ) 50 , 150 , 375mg/m2 . No significant change see WBC , hemoglobin , platelet count , chemistry , liver enzymes CMV IgG titer . At three day 6 month infusion decline B cell count compare pre-infusion level . In 44 % , decline PRA see . The patient receive high dos large decrement antibody titer . GENENTECH , INC. provide Rituximab , label investigational use . Rituximab formulate IV administration sterile product sterile , preservative-free liquid concentrate intravenous ( IV ) administration . STUDY DESIGN : This 12-month phase 2 , prospective , open label study evaluate effect rituximab mycophenolate mofetil ( MMF ) PRA 14 highly sensitized patient complete 8 month trial MMF treatment alone . PRA value obtain study enrollment 6 12 month combine therapy well rate transplant compare evaluated use descriptive analysis . Primary Endpoints : The number subject experience decrement baseline Panel Reactive Antibody value ( PRA I , PRA II ) cPRA ( calculated PRA available ) : baseline , 6 12 month study initiation . Secondary Endpoints : The number subject receive transplant The number subject negative crossmatch transplant . STUDY POPULATION : Patients kidney transplant wait list currently receive hemodialysis Panel Reactive Antibodies ( PRA ) titer level 50 % complete 8 month mycophenolate mofetil ( MMF ) treatment alone . SCREENING : Subjects consent , screen clinically occurrence infection , Tuberculosis exposure protective antibody response prior vaccination . RITUXIMAB DOSAGE AND ADMINISTRATION : The Rituximab dose 1000mg ( 1gm ) give single I.V . infusion 2 dos ( day 1 15 ) . No extra dose give . Rituximab may administer outpatient setting . Hypersensitivity reaction may occur . Premedication , consist acetaminophen ( 1gm ) diphenhydramine ( 50mg equivalent dose ) mouth 30 60 minute prior start infusion consider infusion Rituximab . Rituximab re-administered initial dose regimen . ( MMF ) Mycophenolate mofetil DOSAGE AND ADMINISTRATION : Dosing MMF continue high tolerate dose subject take completion parent study : `` Highly Sensitized Patients : effect mycophenolate mofetil ( MMF ) anti- human lymphocyte antibody ( HLA ) level patient await renal transplant '' . The dose adjust accord standard practice , gastrointestinal tolerance WBC count . CLINICAL AND LABORATORY SAFETY EVALUATIONS : SCREENING : - Medical history documentation rationale treatment patient 's disease Rituximab . - Pregnancy test ( serum urine ) woman childbearing potential must do prior initial Rituximab treatment date . - Medical history include : age , sex , prior transplant history , blood transfusion history , prior pregnancy history , history autoimmune disease , infection history last 5 year , immunization history . - Physical examination , include vital sign , performance status . - Hematology ( within 2 week treatment ) : complete blood count ( CBC ) differential platelet count . - Serum Chemistries : glucose , blood urea nitrogen , serum creatinine , uric acid , total bilirubin , alkaline phosphatase , low density lipoprotein , high density lipoprotein , total protein , albumin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , serum calcium . - Serology Testing appropriate : Hepatitis B , Hepatitis C , HIV - IgG IgM total antibody count . - Drug Monitoring : Baseline = pre-infusion . Serum drug level Ritux also measure safety . Human Anti-Rituximab Antibody ( HACA ) test presence antibody rituximab . - Lymphocyte Sub Group : A sub-group type-B lymphocyte call 'CD-19 Cells ' specifically impacted Rituximab use marker drug efficacy . ON GOING EVALUATIONS Post -Treatment : For safety total IgG IgM level monitor IgG supplement level decrease normal value . Additionally WBC count drop 3.0 result change MMF dose . If serious infection occur MMF discontinue . Patients follow one year initial rituximab infusion . - Hematology : monitor CBC + differential weekly 1 month monthly - Monthly : PRAs monitor monthly 12th month study . The standard PRA value sum anti-bodies produce 2 main group lymphocytes ; Class I Class II . We PRA I PRA II antibody class report separately well PRA report use calculation ( cPRA ) . - Quarterly : Serology Testing appropriate : Hepatitis B , Hepatitis C , HIV , IgG IgM total antibody count . - Monitor Serum Ritux HACA level baseline , 6 month 9 month . - Monitor CD19+ B-cells baseline , week 1 , 2 , 4 , month 3 , 6 , 9 12 .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Hypertension , Renal</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Age range 18 75 , inclusive Able willing give write informed consent comply requirement study protocol Outpatient status Patients Panel Reactive Antibodies ( PRA ) 10 % 8month trial MMF monotherapy Patients updated immunization tetanus , influenza , hepatitis B , pneumococcus Patients negative purified protein derivative ( PPD ) screen tuberculosis ( TB ) within last 6 month . If subject prior history TB positive PPD , documentation adequate treatment require . Women childbearing potential must negative serum pregnancy test prior enrol study agree use medically acceptable method contraception throughout study twelve month ( 1 year ) completion treatment . Men must agree use acceptable method birth control treatment twelve month ( 1 year ) completion treatment . Liver enzymes ALT AST less 2 time normal limit . Active infection Receipt live vaccine within 4 week prior first infusion . Previous treatment rituximab ( MabThera® / Rituxan® ) History multiple recurrent infection define 3 urinary tract infection , 2 episode pneumonia 3 episode otitis/sinusitis one year , two dialysis line peritoneal infection within one year . Infection hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) , lack documentation treatment positive PPD , pregnant breastfeeding , baseline leukopenia , white blood cell count ( WBC ) less 4.0 , thrombocytopenia ( platelet count le 100,000/mm ) difficult treat anemia , hematocrit chronically le 32 intravenous iron EPO ( erythropoietin ) therapy , history severe allergic anaphylactic reaction humanize murine monoclonal antibody . Concomitant malignancies previous malignancy within last five year , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix . History psychiatric disorder Significant cardiac pulmonary disease ( include obstructive pulmonary disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Dialysis</keyword>
	<keyword>Kidney</keyword>
	<keyword>Renal</keyword>
	<keyword>Nephropathy</keyword>
	<keyword>Glomerulonephropathy</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Graft</keyword>
	<keyword>Compatibility</keyword>
	<keyword>Transplant</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Transplantation , Kidney</keyword>
</DOC>